AA
ABUS icon

ALPS Advisors’s Arbutus Biopharma ABUS Stock Holding History

ALPS Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-107,107
Closed -$325K – 995
2023
Q1 		$325K Buy
107,107
+877
+0.8% +$2.47K ﹤0.01% 781
2022
Q4 		$248K Buy
106,230
+24,352
+30% +$58.3K ﹤0.01% 966
2022
Q3 		$156K Sell
81,878
-6,346
-7% -$14.9K ﹤0.01% 1019
2022
Q2 		$239K Sell
88,224
-64,538
-42% -$165K ﹤0.01% 961
2022
Q1 		$455K Sell
152,762
-3,784
-2% -$11.6K ﹤0.01% 444
2021
Q4 		$609K Buy
+156,546
New +$608K 0.01% 465
2019
Q2 		– Sell
-134,053
Closed -$480K – 878
2019
Q1 		$480K Buy
134,053
+6,016
+5% +$23.1K ﹤0.01% 535
2018
Q4 		$490K Buy
+128,037
New +$631K ﹤0.01% 485

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ALPS Advisors's ABUS Position: Q2 2023 in Review

ALPS Advisors sold out of Arbutus Biopharma (ABUS) in Q2 2023, closing a stake of 107,107 shares — an estimated $325K sold.

ALPS Advisors first reported a position in ABUS in Q4 2018 and held it in 8 quarters. The position peaked at $609K in Q4 2021. 111 funds tracked by Wall St. Rank hold ABUS as of Q2 2023.

  • ALPS Advisors reported no remaining Arbutus Biopharma position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 107,107 Arbutus Biopharma shares in Q2 2023, an estimated $325K.
  • ALPS Advisors first reported a position in Arbutus Biopharma in Q4 2018 and held it in 8 quarters.
  • ALPS Advisors's Arbutus Biopharma position peaked at $609K in Q4 2021.
  • 111 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.